EIEmilio Iannitto

Emilio Iannitto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emilio Iannitto has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Antonino Mulè

    Department of Oncology, Haematology, and BMT Unit

    1 shared publication
  • Antonio Craxì

    Section of Gastroenterology & Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, 90127 Palermo, Italy

    1 shared publication
  • Donatella Ferraro

    Microbiology Section, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties ‘G. D’Alessandro’, University of Palermo, 90133 Palermo, Italy

    1 shared publication
  • Emanuele Ammatuna

    Department of Oncology, Haematology, and BMT Unit

    1 shared publication
  • Giuseppina Calvaruso

    Department of Oncology, Haematology, and BMT Unit

    1 shared publication
  • Rosa D. Stefano

    Department of Hygiene and Microbiology

    1 shared publication

Latest Publications

  • Hepatitis B virus reactivation and alemtuzumab therapy

    by Emilio Iannitto, Viviana Minardi, Giuseppina Calvaruso, Antonino Mulè, Emanuele Ammatuna, Rosa D. Trapani, Donatella Ferraro, Vincenzo Abbadessa, Antonio Craxí, Rosa D. Stefano

    Abstract:  Reactivation of hepatitis B virus infection in subjects receiving cytotoxic treatment for heamatological malignancies occurs in 21–53% of chronic HBsAg carriers and in an unknown number of HBsAg negative subjects harbouring occult HBV infection. Immunotherapy with alemtuzumab, a humanized monoclonal antibody against CD52 epitopes on lymphocytes cells produces deep immunosuppression. We describe two subjects with chronic lymphocytic leukaemia and occult HBV infection who developed a virological and biochemical flare of hepatitis B following immunotherapy with alemtuzumab. One of them developed full blown hepatitis with seroreversion from anti‐HBs to HBsAg after four weeks of alemtuzumab therapy. Lamivudine (100 mg die) achieved a complete clinical recovery and HBV‐DNA clearance from blood within 8 weeks. The second patient (HBsAg and HBV‐DNA seronegative, anti‐HBs and anti‐HBc positive before treatment) was kept under prophylaxis with lamivudine up to three months after alemtuzumab. Two months after withdrawal of lamivudine, clinical and laboratory features of acute hepatitis B developed. Lamivudine therapy was restarted and a prompt recovery was obtained with HBsAg and HBV‐DNA clearance.